JP2005533104A5 - - Google Patents

Download PDF

Info

Publication number
JP2005533104A5
JP2005533104A5 JP2004521488A JP2004521488A JP2005533104A5 JP 2005533104 A5 JP2005533104 A5 JP 2005533104A5 JP 2004521488 A JP2004521488 A JP 2004521488A JP 2004521488 A JP2004521488 A JP 2004521488A JP 2005533104 A5 JP2005533104 A5 JP 2005533104A5
Authority
JP
Japan
Prior art keywords
composition
compound
composition according
och
cooh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2004521488A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005533104A (ja
Filing date
Publication date
Priority claimed from US10/195,824 external-priority patent/US6727272B1/en
Application filed filed Critical
Publication of JP2005533104A publication Critical patent/JP2005533104A/ja
Publication of JP2005533104A5 publication Critical patent/JP2005533104A5/ja
Ceased legal-status Critical Current

Links

JP2004521488A 2002-07-15 2003-06-25 慢性関節リウマチを処置するためのレフルノミド類似体 Ceased JP2005533104A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/195,824 US6727272B1 (en) 2002-07-15 2002-07-15 Leflunomide analogs for treating rheumatoid arthritis
PCT/US2003/019956 WO2004006834A2 (en) 2002-07-15 2003-06-25 Leflunomide analogs for treating rheumatoid arthritis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010108822A Division JP2010168402A (ja) 2002-07-15 2010-05-10 慢性関節リウマチを処置するためのレフルノミド類似体

Publications (2)

Publication Number Publication Date
JP2005533104A JP2005533104A (ja) 2005-11-04
JP2005533104A5 true JP2005533104A5 (https=) 2006-06-29

Family

ID=30115011

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004521488A Ceased JP2005533104A (ja) 2002-07-15 2003-06-25 慢性関節リウマチを処置するためのレフルノミド類似体
JP2010108822A Pending JP2010168402A (ja) 2002-07-15 2010-05-10 慢性関節リウマチを処置するためのレフルノミド類似体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010108822A Pending JP2010168402A (ja) 2002-07-15 2010-05-10 慢性関節リウマチを処置するためのレフルノミド類似体

Country Status (5)

Country Link
US (1) US6727272B1 (https=)
EP (1) EP1539143A4 (https=)
JP (2) JP2005533104A (https=)
AU (1) AU2003251611A1 (https=)
WO (1) WO2004006834A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0903345B1 (de) * 1997-08-08 2000-10-04 Aventis Pharma Deutschland GmbH Kristallform von 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)-anilid
US7125902B2 (en) * 2004-05-28 2006-10-24 Unitech Pharmaceuticals, Inc. Methods, compounds, and diagnostics for cancer treatment
WO2006002422A2 (en) 2004-06-24 2006-01-05 Novartis Vaccines And Diagnostics Inc. Compounds for immunopotentiation
US20060024376A1 (en) * 2004-07-30 2006-02-02 The University Of Chicago Methods and compositions for reducing toxicity associated with leflunomide treatment
US7291743B2 (en) * 2005-03-29 2007-11-06 Geneblue Corporation Isoxazole derivatives and methods of treating nitric oxide mediated diseases
JPWO2007026737A1 (ja) * 2005-08-31 2009-03-12 興和株式会社 関節リウマチの予防及び/又は治療法
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
AR060358A1 (es) 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
CN101563082A (zh) * 2006-09-05 2009-10-21 窦德献 治疗免疫介导性皮肤病的组合物和方法
EA200900472A1 (ru) * 2006-09-22 2009-10-30 Ранбакси Лабораторис Лимитед Ингибиторы фосфодиэстеразы iv типа
US20080085912A1 (en) * 2006-10-06 2008-04-10 Unitech Pharmaceuticals, Inc. Isoxazole derivatives and methods of treating diseases
EP2240475B1 (en) 2007-12-20 2013-09-25 Novartis AG Thiazole derivatives used as pi 3 kinase inhibitors
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
JP5820476B2 (ja) 2010-08-24 2015-11-24 アルギアックス ファルマコウティカルス ゲーエムベーハーALGIAX Pharmaceuticals GmbH レフルノミドおよびマロノニトリラマイドの新規の使用
MX343706B (es) 2011-01-31 2016-11-18 Novartis Ag Derivados heterocíclicos novedosos.
PT2771342T (pt) 2011-10-28 2016-08-17 Novartis Ag Derivados de purina e o seu uso no tratamento de doença
WO2013173283A1 (en) 2012-05-16 2013-11-21 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
CN105979947A (zh) 2013-12-06 2016-09-28 诺华股份有限公司 α-同工型选择性磷脂酰肌醇3-激酶抑制剂的剂量方案
US10526279B2 (en) * 2015-06-17 2020-01-07 Biocon Limited Process for the preparation of teriflunomide
RU2018119085A (ru) 2015-11-02 2019-12-04 Новартис Аг Схема введения ингибитора фосфатидилинозитол-3-киназы
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
CN108863970A (zh) * 2017-08-14 2018-11-23 四川省中医药转化医学中心 新化合物及其在治疗炎症或炎症相关疾病方面的应用
KR102696521B1 (ko) * 2021-11-24 2024-08-20 한양대학교 에리카산학협력단 이속사졸 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1533347A (en) * 1976-10-22 1978-11-22 Pfizer Ltd Anthelmintic compounds
FR2639636B1 (fr) * 1988-11-30 1994-03-04 Novapharme Nouveaux composes heterocycliques a activite anticonvulsivante, procede de preparation et compositions therapeutiques les contenant
EP0418667B1 (de) * 1989-09-22 1995-08-16 BASF Aktiengesellschaft Carbonsäureamide
US5814646A (en) * 1995-03-02 1998-09-29 Eli Lilly And Company Inhibitors of amyloid beta-protein production
DE19702988A1 (de) 1997-01-28 1998-07-30 Hoechst Ag Isoxazol- und Crotonsäureamidderivate und deren Verwendung als Arzneimittel und Diagnostika
US20030092706A1 (en) * 2001-11-09 2003-05-15 Johannes Barsig Combination

Similar Documents

Publication Publication Date Title
JP2005533104A5 (https=)
JP2011513196A5 (https=)
JP2007533752A5 (https=)
JP2016503786A5 (https=)
JP2012526854A5 (https=)
JP2007508360A5 (https=)
JP2017222722A5 (https=)
FR14C0020I1 (fr) Compositions pharmaceutiques contenant du fentanyl pour application nasale
ATE430569T1 (de) Neue arzneimittel zur behandlung von chronisch obstruktiver lungenerkrankung
JP2005511547A5 (https=)
JP2006182786A5 (https=)
JP2006518728A5 (https=)
CY1114637T1 (el) 4-[4-({[4-χλωρο-3-(τριφθορομεθυλο)φαινυλο)]καρβαμοϋλ}αμινο)-3-φθοροφαινοξυ]-ν-μεθυλοπυριδινο-2-καρβοξαμιδιο μονοϋδρικο
JP2010511631A5 (https=)
JP2006503809A5 (https=)
JP2002520316A5 (https=)
JP2004532828A5 (https=)
JP2006504738A5 (https=)
JP2008513510A5 (https=)
JP2019501948A5 (https=)
EA201401042A1 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И КОМБИНИРОВАННОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ ИНГИБИТОРЫ HMG-CoA-РЕДУКТАЗЫ И ФОСФОДИЭСТЕРАЗЫ 4, И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ЛЕГКИХ
JP2019537608A5 (https=)
JP2005522492A5 (https=)
JP2009503045A5 (https=)
JP2022552520A5 (https=)